ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2136

Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology

Fabio Cacciapaglia1, Gian Luca Erre 2, Garifallia Sakellariou 3, Ombretta Viapiana 4, Matteo Piga 5, Elena Bartoloni 6, Andreina Manfredi 7, Sergio Colella 1, Floriana Castagna 2, Giacomo Cafaro 8, Martina Dessì 5, Marco Fornaro 1, Alessandro Giollo 9, Silvia Grignaschi 10, Caterina Vacchi 11, Francesca Romana Spinelli 12, Fabiola Atzeni 13 and Elisa Gremese 14, 1Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy, Bari, Italy, 2Specialità Mediche, Azienda Ospedaliero Universitaria di Sassari, Italy., Sassari, Italy, 3Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 4University of Verona, Verona, Italy, 5Rheumatology Unit, Department of Medical Sciences, University and AOU Policlinico of Cagliari, Italy., Cagliari, Italy, 6Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, 7Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, 8Rheumatology Unit, Department of Medicine, University of Perugia, Italy., Perugia, Italy, 9Rheumatology Unit, Department of Medicine, University of Verona, Italy., Verona, Italy, 10Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy., Pavia, Italy, 11Rheumatology Unit, Department of Medical and Surgical Science, University and AOU Policlinico of Modena, Italy., Modena, 12Rheumatology, Department of Internal Medicine and Medical Speciality, Sapienza University of Rome, Italy., Rome, Italy, 13Rheumatology Unit, University of Messina, Messina, Italy., Messina, Italy, 14Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Cardiovascular disease, morbidity and mortality, risk assessment, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients present high cardiovascular (CV) morbidity and mortality. International guidelines suggest estimating CV-risk in these patients, but no indications about the strategy to use are specified. This multicentre cross-sectional study aimed to investigate the performance in real-life setting of three different 10-years CV-risk estimating algorithms in SLE and RA.

Methods: Data of 989 patients with SLE (140 patients; female 85.7%; age 40±16 years; disease duration 155±106 months) and RA (849 patients; female 79.3%; age 61±12 years; disease duration 133±110 months), according to specific classification criteria, were collected since January 2019 in 10 rheumatologic University Hospitals. Clinical and laboratory parameters were registered, and individual CV-risk was calculated using the “Progetto Cuore”, QRisk3 and Reynolds risk scores (RRS), as stated by suitable algorithms. Statistical analysis was performed with appropriate tests using the Statistical System Prism (Graphpad Instat 6.0 – San Diego CA-USA).

Results: Fifty-six (6.6%) RA and 14 (10%) SLE patients had experienced a previous CV event (mainly myocardial- infarction). Among traditional CV-risks RA patients were significantly older (p< 0.0001), hyperlipidaemia was more prevalent in RA then SLE (57.8% vs 37.1%; p< 0.001), and similar prevalence of hypertension and diabetes was recorded. Mean BMI was not significantly different between groups, nevertheless a BMI >25 Kg/m2 was more prevalent in RA than SLE (47.8% vs 14.2% – p< 0.0001). RA patients were more frequently smokers (23.7% vs 13.6% – p=0.007). C-reactive protein was significantly higher in RA compared to SLE patients (6.8±1.1 vs 3.8±0.4 mg/l – p=0.01). Median (IQR) CDAI and SLEDAI were 7 (3-12) and 2 (0-2) in RA and SLE, respectively, and low-disease or remission according to CDAI (< 10) and SLEDAI (< 4) was similar. Sixty-eight percent of SLE patients were on a mean prednisone-dose of 5.9±2.6 mg/day whereas 41% of RA patients took 5.0±2.8 mg/day of prednisone (p< 0.01). All SLE patients were on hydroxychloroquine, 78 (55.7%) were co-treated with an immunosuppressant agent and 9 (6.4%) with belimumab or rituximab. Seventy percent of RA patients were on csDMARDs, mainly methotrexate, and 49.5% used also a biologic agent. CV-risk with QRisk3 results 2 to 3-fold higher compared to RRS and “Progetto Cuore” score in both patient groups. Moreover, QRisk3 and RRS resulted significantly higher in RA compared to SLE (Figure1A). Interestingly, only in RA a positive correlation between CDAI and QRisk3 (r=0.1; p=0.03) was detected (Figure1B).

Conclusion: This multicentre study showed a different performance in SLE and RA patients of the commonly used algorithms to estimate CV-risk in clinical practice. With a good disease activity control, traditional CV-risk factors may differently impact on predictable CV-risk using the “Progetto Cuore” scores, QRisk3 or the RRS. These findings should be considered when CV-risk is estimated routinely in such patients.

A. Estimated % 10-years cardiovascular risk in SLE and RA patients according to “Progetto Cuore”, QRisk3 and Reynolds risk scores.
B. Correlation between CDAI and QRisk3 score in RA patients.


Disclosure: F. Cacciapaglia, None; G. Erre, None; G. Sakellariou, None; O. Viapiana, Abiogen; M. Piga, None; E. Bartoloni, None; A. Manfredi, None; S. Colella, None; F. Castagna, None; G. Cafaro, None; M. Dessì, None; M. Fornaro, None; A. Giollo, None; S. Grignaschi, None; C. Vacchi, None; F. Spinelli, None; F. Atzeni, None; E. Gremese, AbbVie, 5, 8, BMS, 5, 8, Celgene, 5, 8, Janssen, 5, 8, Lilly, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, Sanofi, 5, 8, UCB, 5, 8.

To cite this abstract in AMA style:

Cacciapaglia F, Erre G, Sakellariou G, Viapiana O, Piga M, Bartoloni E, Manfredi A, Colella S, Castagna F, Cafaro G, Dessì M, Fornaro M, Giollo A, Grignaschi S, Vacchi C, Spinelli F, Atzeni F, Gremese E. Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-risk-evaluation-in-systemic-lupus-erythematosus-and-rheumatoid-arthritis-preliminary-results-from-the-cardiovascular-obesity-and-rheumatic-disease-cordis-study-grou/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-evaluation-in-systemic-lupus-erythematosus-and-rheumatoid-arthritis-preliminary-results-from-the-cardiovascular-obesity-and-rheumatic-disease-cordis-study-grou/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology